Formulary Insights—Powered by Petauri’s Post

I just came across this compelling article on the 4 key barriers holding biosimilars back—and how to remove them. For anyone involved in healthcare, pharmaceuticals, or policy-making, this is a must-read. The piece dives into critical obstacles in the biosimilar landscape, including market dynamics, education gaps, and regulatory hurdles, while also offering practical solutions to unlock their full potential. As we strive for better accessibility and affordability in healthcare, understanding and addressing these challenges is crucial. 🔗 Check out the details here: https://lnkd.in/eCQ-aMGq

Join our live panel, on June 11, with biopharma and market access and communication experts from Cencora, on the impact of biosimilars in the U.S. market landscape. We will delve into how to overcome regulatory hurdles, fostering collaborations, and enhancing communication with stakeholders amidst dynamic market changes. Register now: https://lnkd.in/e8-Dz4uU #Biosimilars #Marketaccess

Join our live panel, on June 11, with biopharma and market access and communication experts from Cencora, on the impact of biosimilars in the U.S. market landscape. We will delve into how to overcome regulatory hurdles, fostering collaborations, and enhancing communication with stakeholders amidst dynamic market changes. Register now: https://lnkd.in/enR3NEEr #Biosimilars #Marketaccess

Thoughts on this? >> What Coherus' $40M sale of its Humira biosimilar says about the crowded market >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #productmarketing #pharma #biotech

As of February, brand-name Humira controls 96% of the adalimumab market, according to the latest quarterly report from Samsung Bioepis. Biosimilars gained just one percentage point of market share since an earlier version of the Samsung report released six months ago, a stark reminder that real competition for AbbVie biologic could take years. So what’s stopping biosimilars from breaking through? One recent IQVIA report found that while shifting to adalimumab biosimilars would save up to $6 billion for the US health system, PBMs would lose up to 84% of profit — a major reason very few large payers have come on board. https://lnkd.in/dJ8MSQyd

Ready to take your biopharma company to the next level? Our whitepaper uncovers the seven key factors for a successful first drug launch in Europe, including pricing strategies, market positioning, and common pitfalls to avoid. Learn from 4,500 data points and expert insights to build a winning launch strategy. Discover our insights: skp.link/yhq7 #BetterMarketAccess #SimonKucher #Biopharma #FirstDrugLaunch #CommercialExcellence

Ready to take your biopharma company to the next level? Our whitepaper uncovers the seven key factors for a successful first drug launch in Europe, including pricing strategies, market positioning, and common pitfalls to avoid. Learn from 4,500 data points and expert insights to build a winning launch strategy. Discover our insights: skp.link/yhq7 #BetterMarketAccess #SimonKucher #Biopharma #FirstDrugLaunch #CommercialExcellence

Ready to take your biopharma company to the next level? Our whitepaper uncovers the seven key factors for a successful first drug launch in Europe, including pricing strategies, market positioning, and common pitfalls to avoid. Learn from 4,500 data points and expert insights to build a winning launch strategy. Discover our insights: skp.link/yhq7 #BetterMarketAccess #SimonKucher #Biopharma #FirstDrugLaunch #CommercialExcellence

Ready to take your biopharma company to the next level? Our whitepaper uncovers the seven key factors for a successful first drug launch in Europe, including pricing strategies, market positioning, and common pitfalls to avoid. Learn from 4,500 data points and expert insights to build a winning launch strategy. Discover our insights: skp.link/yhq7 #BetterMarketAccess #SimonKucher #Biopharma #FirstDrugLaunch #CommercialExcellence